secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGENUS INC (AGEN)
CIK:        0001098972
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001157523-23-001274
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agenus Q2 2023 net loss $73.4M; bot/bal combo mOS 20.9 months in CRC, FDA Fast Track
--------------------------------------------------------------------------------

- Q2 revenue $25.3M, net loss $73.4M ($0.20 EPS); cash $157.6M at June 30, down from $193.4M at Dec 2022.
- Bot/bal combo in 3L+ Non-MSI-H CRC: mOS 20.9 months vs 12.9 SOC; ORR 23% vs 2.8%; FDA Fast Track granted.
- ACTIVATE Phase 2 CRC and melanoma trials on target to fully enroll by end of 2023; BLA submission planned in 2024.
- AGEN2373 monotherapy shows clinical responses in prostate, ampullary, vulvar cancers; first CD137 agonist with no hepatic toxicity.
- Leadership appointments: Robin Taylor (CCO), Homa Yeganegi (Chief Product Strategy & Global Medical Affairs), Stephanie Fagan (CCO).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1098972/000115752323001274/0001157523-23-001274-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1098972/000115752323001274/a53512783.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-001274

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer